U.S. markets closed

MiNK Therapeutics, Inc. (INKT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0000-0.1000 (-4.76%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.1000
Bid1.8300 x 2900
Ask2.4900 x 800
Day's Range2.0000 - 2.3200
52 Week Range1.0900 - 22.1550
Avg. Volume479,917
Market Cap67.55M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2040
Earnings DateAug 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for INKT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MiNK Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 07/22/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    MiNK Therapeutics to Participate at Upcoming Investor Conferences

    NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will participate in two investor conferences in September: HC Wainwright 24th Annual Global Investment ConferenceFireside chat webcast will be available beginning at 7:0

  • Simply Wall St.

    Do Insiders Own Lots Of Shares In MiNK Therapeutics, Inc. (NASDAQ:INKT)?

    If you want to know who really controls MiNK Therapeutics, Inc. ( NASDAQ:INKT ), then you'll have to look at the makeup...

  • GlobeNewswire

    MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results

    Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned for 2H2022Under the leadership team of Dr. Joy Zhou, completed internal cGMP production of AgenT-797 with expansion capacity to treat >700,000 patients/yearAgenT-797 for the treatment of infections and viral ARDS identified as selectable for funding by DARPA; contract negotiations underway NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- MiNK Therape